Lenvatinib Mesylate Patent Expiration

Lenvatinib Mesylate is Used for treating thyroid carcinoma, including differentiated thyroid cancer, by administering Lenvima as a suspension. It was first introduced by Eisai Inc in its drug Lenvima on Feb 13, 2015.


Lenvatinib Mesylate Patents

Given below is the list of patents protecting Lenvatinib Mesylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Lenvima US10259791 High-purity quinoline derivative and method for manufacturing same Aug 26, 2035 Eisai Inc
Lenvima US10259791

(Pediatric)

High-purity quinoline derivative and method for manufacturing same Feb 26, 2036 Eisai Inc
Lenvima US10407393 High-purity quinoline derivative and method for manufacturing same Aug 26, 2035 Eisai Inc
Lenvima US10407393

(Pediatric)

High-purity quinoline derivative and method for manufacturing same Feb 26, 2036 Eisai Inc
Lenvima US11090386 Method for suppressing bitterness of quinoline derivative Feb 23, 2036 Eisai Inc
Lenvima US11090386

(Pediatric)

Method for suppressing bitterness of quinoline derivative Aug 23, 2036 Eisai Inc
Lenvima US11186547 High-purity quinoline derivative and method for manufacturing same Aug 26, 2035 Eisai Inc
Lenvima US11186547

(Pediatric)

High-purity quinoline derivative and method for manufacturing same Feb 26, 2036 Eisai Inc
Lenvima US7253286 Nitrogen-containing aromatic derivatives Oct 24, 2025 Eisai Inc
Lenvima US7253286

(Pediatric)

Nitrogen-containing aromatic derivatives Apr 24, 2026 Eisai Inc
Lenvima US7612208 Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same Sep 19, 2026 Eisai Inc
Lenvima US7612208

(Pediatric)

Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same Mar 19, 2027 Eisai Inc
Lenvima US9006256 Antitumor agent for thyroid cancer Jul 27, 2027 Eisai Inc
Lenvima US9006256

(Pediatric)

Antitumor agent for thyroid cancer Jan 27, 2028 Eisai Inc


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lenvatinib Mesylate's patents.

Given below is the list of last 4 months of legal activities going on the following patents of Lenvatinib Mesylate.

Event Date Patent/Publication
Patent litigations
List of References cited by applicant and considered by examiner 08 Jul, 2024 US20190388420A1
Notice of Allowance and Fees Due (PTOL-85) 08 Jul, 2024 US20190388420A1
Information Disclosure Statement (IDS) Form (SB08) 01 Jul, 2024 US20190388420A1
Information Disclosure Statement considered 29 Jun, 2024 US20190388420A1
Examiner's search strategy and results 21 Jun, 2024 US20210330673A1
List of references cited by examiner 21 Jun, 2024 US20210330673A1
Final Rejection 21 Jun, 2024 US20210330673A1
Examiner's search strategy and results 21 Jun, 2024 US20210330673A1
Lapse of the patent in a contracting state 07 Jun, 2024 EP3619232B1
Response to Election / Restriction Filed 24 May, 2024 US20230201342A1
Applicant Arguments/Remarks Made in an Amendment 24 May, 2024 US20230201342A1
Claims 24 May, 2024 US20230201342A1
Response to Election / Restriction Filed 24 May, 2024 US20230201342A1
Applicant Arguments/Remarks Made in an Amendment 13 May, 2024 US20220062263A1
Amendment/Request for Reconsideration-After Non-Final Rejection 13 May, 2024 US20220062263A1
Information Disclosure Statement (IDS) Form (SB08) 29 Apr, 2024 US20220409724A1
Opposition Filed 10 Apr, 2024 EP3619232B1
Examiner Interview Summary Record (PTOL - 413) 08 Apr, 2024 US20220062263A1
Notice of further oppositions to opponent(s) 27 Mar, 2024 EP3619232B1
Communication of a notice of opposition and request to file observations 27 Mar, 2024 EP3619232B1
Recordation of Patent Grant Mailed 26 Mar, 2024 US11938135B2
eGrant day-of Notification 25 Mar, 2024 US11938135B2
Issue Notification 05 Mar, 2024 US11938135B2



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳